Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

Failure to Report Ambien Patent Agreements

The U.S. Federal Trade Commission (FTC) notified Sanofi-Aventis U.S. LLC, Watson Pharmaceuticals, Inc., and Synthon Holding B.V., alleging that the companies violated the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) by failing to inform antitrust authorities about drug patent agreements involving Sanofi’s insomnia drug Ambien CR. The MMA requires companies to file such agreements with the FTC and U.S. Department of Justice within 10 business days of their execution, or else face a civil penalty of $11,000 per day. The FTC decided not to recommend an enforcement action because the violation did not appear to have harmed consumers or benefitted the companies, and the failure to file did not appear to have been a deliberate effort to evade the requirements of the MMA.

Misconduct Type
Antitrust
Enforcement Agency
FTC
Contracting Party
None
Court Type
N/A
Disposition
Investigative Finding
Date of FTC Advisory Letter
5/9/2011
Contractors Involved Penalty
Total
Sanofi-Aventis $0
Further Information Released
FTC Advisory Letter 5/21/2011
FTC Press Release 5/21/2011

Federal Contractor Misconduct Database